Targeting survivin in cancer therapy

Author： Pennati Marzia   Folini Marco   Zaffaroni Nadia  

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.12, Iss.4, 2008-04, pp. : 463-476

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting survivin in cancer: patent review

By Kanwar Jagat R   Kamalapuram Sishir K   Kanwar Rupinder K  

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 12, 2010-12 ,pp. : 1723-1737

Informa Healthcare

Access to resources Recommend Favorite

Inhibiting survivin expression: potential in cancer therapy?

By  

Inpharma, Vol. 1, Iss. 1314, 2001-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Survivin as a Prognostic/Predictive Marker and Molecular Target in Cancer Therapy

By  

Current Medicinal Chemistry, Vol. 19, Iss. 22, 2012-08 ,pp. : 3679-3688

Bentham Science Publishers

Access to resources Recommend Favorite

Drugs targeting integrins for cancer therapy

By Binder Mascha   Trepel Martin  

Expert Opinion on Drug Discovery, Vol. 4, Iss. 3, 2009-03 ,pp. : 229-241

Informa Healthcare

Access to resources Recommend Favorite

Targeting Ubc9 for cancer therapy

By Mo Yin-Yuan   Moschos Stergios J  

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 6, 2005-12 ,pp. : 1203-1216

Informa Healthcare

Access to resources Recommend Favorite